News
Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...
Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs.
